(News Bulletin 247) – Bayer announces today that after a two-year follow-up, Xarelto (rivaroxaban) has been associated with a reduced risk of adverse kidney effects and all-cause mortality in patients with fibrillation atrial nonvalvular (NAVF – a form of cardiac arrhythmia) and advanced chronic renal failure (CKD), compared to vitamin K antagonists (VKA) which are associated with worsening kidney function compared to anticoagulants oral non-vitamin K antagonists (NOAC).
Avoiding worsening kidney function is an important clinical consideration beyond stroke prevention when it comes to selecting an oral anticoagulant in patients with NVAF, Bayer points out.
Thus, the study supports the use of Xarelto in this patient group, including cautious use in patients with CKD stage 4 (use of Xarelto is not recommended in patients whose clearance creatinine is
‘Xarelto is the only NOAC that provides such broad evidence on the reduction of adverse effects on the kidneys compared to VKAs’, concludes the laboratory.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
